Originally published In Press as doi:10.1074/jbc.M112351200 on March 7, 2002
J. Biol. Chem., Vol. 277, Issue 20, 17892-17900, May 17, 2002
Pro-inflammatory Cytokines Tumor Necrosis Factor
and
Interleukin-6 and Survival Factor Epidermal Growth Factor Positively
Regulate the Murine GSTA4 Enzyme in Hepatocytes*
Fabienne
Desmots
,
Mary
Rissel
,
David
Gilot§,
Dominique
Lagadic-Gossmann
,
Fabrice
Morel
,
Christiane
Guguen-Guillouzo§,
André
Guillouzo
¶, and
Pascal
Loyer§
From
INSERM U456, Faculté de Pharmacie,
Université de Rennes I, 35043 Rennes Cedex and
§ INSERM U522, Hôpital Pontchaillou,
35033 Rennes Cedex, France
Received for publication, December 24, 2001, and in revised form, February 19, 2002
 |
ABSTRACT |
We hypothesized that glutathione transferases
could be induced and may participate to cellular defenses against the
oxidative stress occurring during liver regeneration. Here, we
evidenced that murine GSTA1 (mGSTA1), A4, Pi, and Mu are
up-regulated during mouse liver regeneration, exhibiting a biphasic
pattern of induction correlating early G1 phase and
G1/S transition of the cell cycle. Using confocal
microscopy immunolocalization and subcellular fractionation, mGSTA4 was
demonstrated in both mitochondria and cytosol and found preferentially
increased in cytosol during liver regeneration. In addition, mGSTA4 was
induced in vivo and in cultured hepatocytes by tumor
necrosis factor
(TNF
), interleukin-6 (IL-6), and epidermal growth factor (EGF), factors that play crucial roles in hepatocyte survival and proliferation during liver regeneration. However, the
mitogenic effect of EGF was not responsible for the induction of
mGSTA4. In transient transfections, IL-6 and EGF, but not TNF
, transactivated the human GSTA4 (hGSTA4) promoter cloned upstream of the luciferase reporter gene suggesting that IL-6 and EGF
up-regulated hGSTA4 at a transcriptional level, whereas TNF
could
rather act at a post-transcriptional level. The inhibition of
phosphoinositide 3-kinase, p38 MAPK, and MEK/ERK signaling pathways,
using specific inhibitors, prevented EGF-dependent
induction of mGSTA4 and transactivation of hGSTA4 promoter. Altogether,
these data favor the conclusion that, in regenerating hepatocytes,
several GST isoforms are induced and that cytokines TNF
and IL-6 and
survival factor EGF positively regulate mGSTA4 via survival signaling pathways.
 |
INTRODUCTION |
Quiescent, differentiated hepatocytes are able to re-enter the
cell cycle and proliferate to restore the liver mass following liver
deficits resulting from surgical removal or caused by chemicals and
viruses. Entry into and progression through early G1 phase of the cell cycle, also called priming (1), are induced by the
cytokines tumor necrosis factor
(TNF
)1 (2, 3) and
interleukin-6 (IL-6) (4) and are required for the hepatocytes to fully
respond to growth factors (3). TNF
binding to its type 1 receptor
successively activates NF
B (5), IL-6 expression, and STAT3 (6, 7) in
the early G1 phase, which constitute a key signaling
pathway during hepatocyte proliferation (4, 8). The late G1
progression and commitment to DNA replication are controlled by growth
factors (9-11) including hepatocyte growth factor, transforming growth
factor-
, and epidermal growth factor (EGF) (1) through the
activation of the MEK/ERK pathway (11).
Several lines of evidence indicate that partial hepatectomy (PH) is
rapidly followed by an oxidative stress due to increased reactive
oxygen species (ROS) and nitric oxide (NO) production leading to lipid
peroxidation (12-14).
Regarding ROS, TNF
is now recognized as playing a crucial role in
the production of these species during liver regeneration. In support
of such a role, it is worth noting that the multimerization of TNF
type I receptor following binding of TNF
has indeed been shown to
lead to recruitment of TRAF (TNF receptor-associated protein), a
protein involved in the signaling pathway regulating ROS production in
mitochondria (15), probably through the inhibition of complex III of
the electron transport chain (16).
Both ROS and NO have been demonstrated to contribute
significantly to induce hepatocyte proliferation. Indeed, in transgenic mice with targeted disruption of TNF
type I receptor
(TNFRI) or of the type II nitric-oxide synthase (iNOS), the
enzyme that catalyzes the formation of NO from arginine, hepatocyte
proliferation after PH is strongly impaired (2, 12). In this context,
it then appears that TNF
-related oxidative stress functions as a signaling pathway rather than eliciting deleterious effects. Such a
function is mediated through the activation of redox-sensitive proteins, especially the transcription factor NF
B (17), which on one
hand allows the occurrence of proliferation by transactivating cell
cycle genes such as c-fos and c-jun controlling
the G0/G1 transition, and on the other hand,
attenuates deleterious responses resulting from oxidative stress
(e.g. activation of caspases by trans-activating the
anti-apoptotic gene BclXL that prevents activation
of caspases (18)).
NF
B also induces the mitochondrial uncoupling protein UCP-2 (13) and
iNOS (19), both of which contribute to reduce oxidative stress (1).
UCP2, an inner mitochondrial channel for protons, plays a major role in
limiting production of ROS (13) by dissipating the electrochemical
gradient. NO, whose production is enhanced by induction of iNOS,
although it participates in lipid peroxidation (14), also exhibits a
cytoprotective effect by preventing apoptosis through
S-nitrosylation of caspases, which strongly inhibits caspase activities (20). This last mechanism is most likely involved in liver
regeneration because in iNOS knock-out mice, PH is followed by a
strongly increased caspase-3 activity and hepatocyte death (12). Along
with the TNF
-dependent activation of antioxidant defenses, it is worth noting that cytokine IL-6 and growth factors have
also been shown to favor hepatocyte survival during liver regeneration
through stimulation of anti-apoptotic gene products (21,
22).
In normal hepatocytes, an excess of ROS is also neutralized through the
action of thiols, especially glutathione (GSH), of which the content is
increased during liver regeneration (21). In addition,
glutathione S-transferases (GST) of the alpha class detoxify organic hydroperoxides and protect cells against oxidative stress (22). For instance, transfection of hGSTA2 in K562 cells results
in cell protection toward H2O2-induced lipid
peroxidation (23). The GSTA4 enzyme, the
subunit that exhibits the
highest activity against 4-hydroxynonenal (4-HNE) (24, 25), also
efficiently protects against oxidative damage mediated by this
cytotoxic product of lipid peroxidation generated by ROS overproduction
(26). In addition, we have recently demonstrated that ROS
overproduction induced by hepatic iron overload is correlated with an
increase in mGSTA4 expression (27).
These observations suggest that GST enzymes could participate in
defenses against oxidative stress during liver regeneration. However,
to date, little is known about regulation of GST expression and
activity during liver regeneration. Lee and Boyer (28) have reported a
decrease in mRNA levels of several GSTs at 12 h post-PH, whereas Mori et al. (29) have shown a higher expression of
GSTPi after 2 and 3 days post-PH. To our knowledge, no study has
attempted to correlate the expression of GSTs with the oxidative stress occurring during the first hours following PH.
The aim of this paper was, first, to study the expression and
activities of several GST subunits, including the mGSTA4 isoform, during the liver regeneration after a two-thirds hepatectomy in mouse. Then, we investigated whether oxidative stress, the
pro-inflammatory cytokines TNF
and IL-6, and growth/survival factor
EGF, which are involved in proliferation and survival of hepatocytes
during liver regeneration, may regulate the expression of mGSTA4 both in vivo and in hepatocytes in primary culture.
 |
EXPERIMENTAL PROCEDURES |
Antibodies--
The rabbit polyclonal antibody against a mGSTA4
peptide was characterized in our laboratory (30). The other antibodies
were purchased as follows: rabbit polyclonal anti-human GSTA1,
GSTMu, and GSTPi antisera from Biotrin, Dublin, Ireland; rabbit
polyclonal anti-cytochrome c from Santa Cruz Biotechnology,
Santa Cruz, CA; monoclonal anti-cytochrome c oxidase from
Molecular Probes, Eugene, OR; monoclonal anti-phospho-p44/42 MAPK
(Thr-202/Tyr-204) and polyclonal anti-p44/42 MAPK from Cell Signaling
Technology, Beverly, MA; anti-phosphorylated-AKT (Ser-473) from New
England Biolabs, Beverly, MA; and anti-albumin from ICN
Pharmaceuticals, Orsay, France; horseradish peroxidase-linked rabbit
antiserum from Bio-Rad, Ivry sur Seine, France; and mouse and goat
anti-rabbit rhodamine-conjugated IgG from Santa Cruz Biotechnology.
Animal Experiments--
Balb/c male mice (8 weeks old, Janvier
laboratories, Le Genest, France) were subjected to 70% partial
hepatectomy under ether anesthesia and were killed at various times
post-PH. As controls, animals underwent a sham operation consisting of
a laparotomy without tissue resection.
L-N6-(1-Iminoethyl)lysine
dihydrochloride (NIL; Calbiochem) was injected intraperitoneally
at a dosage of 40 µg/g of body weight in normal and hepatectomized
animals 1 h before the surgery. Animals were killed 2 h after
NIL injection. TNF
, IL-6 (Promocell, Heidelberg, Germany), and EGF
(Promega, St. Quentin Fallavier, France) were given intraperitoneally
in 0.2 ml of sterile pyrogen-free saline (0.9% NaCl) with 0.1% bovine
serum albumin at 40, 80, and 125 ng/g of body weight, respectively.
Control animals received the corresponding sterile saline vehicle.
Animals were killed 2 h after TNF
and IL-6 injection and 6 or
24 h after EGF injection.
Isolation and Culture of Hepatocytes--
Mouse hepatocytes were
isolated by the two-step perfusion procedure using 0.025% collagenase
D (Roche Diagnostics, Meylan, France) as previously described (31).
Isolated hepatocytes were resuspended in Williams' medium E
(Invitrogen) containing penicillin G/streptomycin (100 IU/ml), 1 mg/ml serum bovine albumin, 5 µg/ml bovine insulin, and 10% fetal
calf serum (Invitrogen), plated at a density of
6.104/cm2, and maintained at 37 °C under
atmosphere of 5% CO2, 95% air. EGF was added at 50 ng/ml
and TNF
and IL-6 at 20 ng/ml 24 h after cell seeding. Specific
inhibitors Ly 294002, SB 203580 (Calbiochem), and U0126 (Promega) of
PI3K, p38 MAPK, and MEK, respectively, were added 1 h prior to EGF
stimulation at final concentrations of 15, 12, and 50 µM, respectively.
RNA Extraction and Northern Blot Analysis--
Total RNA from
cells or liver biopsies were isolated using an SVRNA extraction kit
(Qiagen, Valencia, CA). Ten µg of total RNA from each sample were
used for Northern blot analysis. Blots were hybridized with the
corresponding 32P-labeled cDNA probe
([
-32P]dCTP, 3000 Ci/mmol, Amersham Biosciences) at
65 °C overnight. Blots were washed at moderate stringency and
exposed to radiograph films. The 18 S ribosomal probe was used as control.
Protein Extraction and Western Blot Analysis--
Cultured
hepatocytes and liver biopsies were homogenized in lysis buffer (HEPES,
pH 7.5, 50 mM, NaCl 150 mM, EDTA 1 mM, EGTA 2.5 mM, 0.1% Tween 20, 10% glycerol,
-glycerophosphate 10 mM, sodium fluoride 1 mM, sodium orthovanadate 0.1 mM,
phenylmethylsulfonyl fluoride 0.1 mM, leupeptin 10 µg/ml,
and aprotinin 10 µg/ml). CDK1 was purified from liver extracts using
p9CKShs1 beads and recovered with sample buffer as described
previously (9). Protein concentrations were determined using the
Bradford method. Proteins were fractionated by SDS-PAGE (12.5%),
transferred to a polyvinylidene difluoride membrane and incubated
further for 2 h in PBS containing 3% bovine serum albumin and
then overnight with primary antibody. Membranes were washed twice
before incubation with secondary antibody for 1 h. Proteins of
interest were visualized using the chemiluminescence reagent ECL (Interchim).
Determination of Intracellular MDA and 4-HNE Levels--
MDA and
4-HNE levels were determined using lipid peroxidation assay kits
(Calbiochem). Liver biopsies were washed in ice-cold 0.9% NaCl and
sonicated in 20 mM Tris-HCl, pH 7.4, to ~10% (w/v). Liver extracts were centrifuged at 3000 × g for 10 min
at 4 °C, and the supernatant was collected prior to determination of
total protein concentration and the MDA and 4-HNE colorimetric assays.
Mitochondrion Isolation--
Liver mitochondria were isolated
from freshly harvested livers by differential centrifugation in
ice-cold H medium containing 210 mM mannitol, 70 mM sucrose, and 2 mM HEPES buffer (pH 7.4) (32). The purified pellets were suspended in 200 µl of buffer containing 150 mM KCl, 0.5 mM malonate, 0.1 mM oxoglutarate, and 10 mM HEPES.
GST Activity Assays--
GST activities toward
1-chloro-2,4-dinitrobenzene (CDNB) and ethacrynic acid (EA) were
determined by spectrometric analysis (33, 34) of total proteins.
GST activity toward 4-HNE was quantified using a high pressure liquid
chromatography method as described previously (27).
Immunohistochemistry--
Mice were anesthetized and perfused
through the portal vein with 4% paraformaldehyde in 0.1 M
sodium cacodylate for 15 min at a flow rate of 10 ml/min. Tissue
fragments were washed in 0.1 M PBS for 4 h and in 10%
glycerol-PBS overnight and were frozen in liquid nitrogen-cooled
isopentane. Frozen tissue sections were mounted on glass slides coated
with 10% gelatin in PBS and incubated in PBS containing 3% bovine
serum albumin for 30 min. They were then covered with a solution of
anti-rabbit GSTA4 (1/100) or anti-rabbit cytochrome c
(1/100) antiserum for 1 h at room temperature. Sections were
washed with PBS, incubated for 2 h with goat anti-rabbit IgG
conjugated to rhodamine (1/200), washed, and mounted. Serial z-axis optical analysis of sections was done at 1-µm
intervals using a laser scanning confocal microscope (Confocal Leica
TCS NT).
[3H]Thymidine Incorporation--
The rate of DNA
synthesis was measured by incubating cultured hepatocytes with
[methyl-3H]thymidine (5 Ci/mmol, Amersham
Biosciences) at 2 µCi/35-mm Petri dish for 24 h. Cells were
sonicated in PBS, and [methyl-3H]thymidine
incorporation was measured after DNA precipitation in 15%
trichloroacetic acid.
Reporter Gene Constructs and Transient Transfection in Primary
Cultured Mouse Hepatocytes--
Two DNA fragments corresponding to the
5'-flanking region of the hGSTA4 gene (1571 and 165 bp upstream of exon 1) characterized previously (35) were cloned
into the pGL3 basic vector (Promega) upstream of the firefly luciferase
reporter gene. The pRL-CMV vector encoding Renilla
luciferase and pGL3-GSTA4-(1-1571) or pGL3-GSTA4-(1-165) were
co-transfected in 24-h cultured hepatocytes using cationic lipids
according to Gilot et al. (36). Dual luciferase assays
(firefly and Renilla) were done using a Promega kit. pGL3 basic (a promoterless pGL3-luciferase construct) and pGL3 promoter (pGL3-luciferase construct with the SV40 promoter) vectors were transfected providing negative and positive firefly luciferase controls.
Statistical Analysis--
Values were expressed as the mean ± S.D. Student's t test was used for the estimation of
statistical significance. A p value less than 0.05 was
considered statistically significant.
 |
RESULTS |
Induction of Several GST Isoforms during Liver
Regeneration--
The expression of the different GST isoforms was
analyzed during liver regeneration over a 96-h period after a
two-thirds hepatectomy of Balb/c mice. To ensure that
liver regeneration occurred as previously described, the
relative mRNA levels of the two cell cycle genes, cyclin D1 and
CDK1, were analyzed. A clear induction of cyclin D1 transcripts was
observed between 30 and 96 h, whereas the level of CDK1 mRNA
was increased between 48 and 96 h post-PH with a maximal
expression at 72 h (Fig.
1A) as previously reported
(37).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of cell cycle markers and GSTs
during mouse liver regeneration. Northern blot analysis of cyclin
D1 and CDK1 mRNAs (A) and mGSTA4, A1, Mu, and Pi
mRNAs (B). Total RNAs were prepared from the livers of
partially hepatectomized and sham-operated animals at the indicated
times and from normal liver (NL). The corresponding 18 S
mRNAs are presented as controls of total RNA loading.
|
|
Levels of mGSTA4, A1, and Pi mRNAs were augmented during liver
regeneration exhibiting a biphasic induction of expression (Fig.
1B). An initial increase was observed within 1 h
post-PH, and mRNA levels remained high for 12 to 24 h. The
second peak of induction took place at 40-48 h, and the increase in
transcript levels was observed until 72-96 h. In sham-operated mice,
mGSTA4, A1, and Pi mRNA levels showed a transient and moderate
increase between 1 and 8 h post-PH but not thereafter. mGSTMu
mRNAs were detected at very low levels, and no significant change
was observed during the first 96 h of regeneration.
mGSTA4, A1, Pi, and Mu proteins were further investigated by Western
blot (Fig. 2A). Expression of
mGSTA4, A1, Pi, and Mu proteins exhibited a biphasic pattern as
observed for mRNAs. The first induction occurred between 0.5 and
4 h after PH; mGSTA1 was very transiently induced at 0.5 h,
whereas up-regulation of mGSTA4, Mu, and Pi remained elevated between
0.5 and 4 h. The second induction of the four GST proteins took
place between 24 and 72 h depending upon the GST isoforms. In
sham-operated mice, a slight increase of mGSTA4, A1, Mu, and Pi
proteins was also detected at 1 and 12 h post-PH as observed with
the corresponding mRNAs, which returned to control values
thereafter except for mGSTPi, which remained elevated until 48 h.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 2.
GST expression and activity during liver
regeneration. A, Detection of mGSTA4, A1, Mu, and Pi
proteins. Western blots were performed on total proteins using
antibodies directed against each GST isoform. B, CDNB (a
common substrate of GST) (a and d), 4-HNE
(a specific substrate of GSTA4) (b), and EA (a specific
substrate of GSTPi) (c) activities measured in the cytosols
of livers after partial hepatectomy (dark circles) or sham
operation (dark squares). These data are representative of
three different experiments (Student's t test; *,
p < 0.05).
|
|
To confirm the induction of several GSTs, during the first hours
post-PH, we measured GST activities using three different substrates:
CDNB, a common substrate for mGSTA4, A1, Mu, and Pi; and 4-HNE and EA,
specific substrates for GSTA4 and GSTPi, respectively (22). GST
activities measured with CDNB, 4-HNE, and EA were all significantly
increased between 0.5 and 2 h after PH compared with sham-operated
animals. The induction of GST expression observed between 24 and
72 h was also correlated with a strong induction of GST activities
using CDNB as a substrate (Fig. 2B).
mGSTA4 Is Located in the Cytosol and Mitochondria of
Hepatocytes--
The subcellular localization of mGSTA4 was analyzed
in normal mouse liver using the indirect immunofluorescence technique and confocal microscopy (Fig.
3A). A punctuated staining
typical of a mitochondrial distribution was observed for cytochrome
c whereas mGSTA4 exhibited both a punctuated and an intense
homogeneous cytosolic staining.

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 3.
mGSTA4 immunolocalization in
liver. A, mGSTA4 immunolocalization in mitochondria and
cytosol of normal liver using confocal microscopy. a,
control reaction with purified immunoglobulins of the pre-immune serum
and then with anti-rabbit immunoglobulins conjugated to rhodamine.
b and c, immunostaining with rabbit anti-GSTA4
(b) and cytochrome c (c) antibodies.
Bars, 10 µm. B and C, Western blot
analysis of mitochondrial markers and mGSTA4 expression. Equal amounts
of mitochondrial (M) and cytosolic (C) proteins
of normal (NL), 1- or 24-h regenerating (PH1,
PH24), and 24-h "sham" (S24) livers were
fractionated by SDS-PAGE (12.5%) and blotted with specific cytochrome
c, cytochrome c oxidase, and albumin
(B) and mGSTA4 (C) antibodies.
|
|
To confirm these results, mGSTA4 protein expression was analyzed by
Western blot in the cytosol and mitochondria of normal or regenerating
livers after cell fractionation. The reliability of the cell
fractionation was demonstrated in cell extracts from normal and 24-h
post-PH regenerating livers by performing Western blots of the
mitochondrial cytochrome c and cytochrome oxidase proteins,
which were detectable mainly in mitochondrial fractions while albumin
was observed only in cytosols (Fig. 3B).
By Western blot the mGSTA4 protein was detectable in both mitochondrial
and cytosolic fractions from normal liver, regenerating livers 1 and
24 h post-PH, and sham-operated livers 24 h post-laparotomy (Fig. 3C). The signal obtained in cytosols was much higher
than in mitochondria and was increased at 1 and 24 h post-PH
compared with normal and sham-operated animals. No change in mGSTA4
level was found in mitochondrial extracts during liver regeneration even after a longer exposure time of the blots (data not shown).
TNF
, IL-6, and EGF, but Not Lipid Peroxidation,
Induce mGSTA4 Expression in Vivo--
During the first hours post-PH,
ROS are produced in mitochondria (13), although NO is released. These
compounds contribute to enhanced lipid peroxidation (14).
To determine whether 4-HNE and MDA, two metabolites known to induce
GSTA4 (38), could be responsible for the early induction of mGSTA4
following PH, the levels of 4-HNE and MDA, were measured in 1-h
regenerating livers, and found to be increased by a 3-fold factor
(p < 0.001) when compared with normal (Fig.
4A) or sham-operated animals
(data not shown). We also measured lipid peroxidation by analyzing
4-HNE/MDA levels and mGSTA4 expression by Western blot in mice injected
with the selective inhibitor of iNOS,
L-N6-(1-Iminoethyl)lysine
dihydrochloride, which blocked the rise of NO production and lipid
peroxidation in hepatectomized liver (14). The level of lipid
peroxidation was strongly decreased in both nonhepatectomized (25-fold;
p < 0.01) and 1-h regenerating (3.9-fold;
p < 0.001) livers of NIL-treated mice when compared with normal and hepatectomized animals that had not been injected with
NIL, respectively (Fig. 4A). The levels of mGSTA4 were not affected by NIL treatment in regenerating liver, whereas in normal liver, injection of NIL increased mGSTA4 expression (Fig.
4B). These results therefore favor the conclusion that the
increase in 4-HNE and MDA content after PH did not trigger mGSTA4
induction.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of lipid peroxidation, IL-6,
TNF , and EGF on mGSTA4 expression.
A, the lipid peroxidation assay was carried out by measuring
MDA + 4-HNE levels in liver extracts of normal and hepatectomized
mice 1 h post-PH, injected or not with NIL (40 µg/g of body
weight) 1 h prior to PH. B, Western blot analysis of
mGSTA4 expression in the same livers. Total proteins were prepared from
regenerating or quiescent livers of control and NIL-injected mice.
C, Western blot analysis of mGSTA4 and A1 expression in
livers of control (injected with saline buffer) and TNF - or
IL-6-injected mice. D, Western blot analysis of mGSTA4 and
CDK1 in normal livers (NL) and in livers of control
(injected with saline buffer) and EGF-injected mice. Expression of
mGSTA4 and CDK1 was studied 6 and 24 h after EGF administration.
As positive controls of proliferation and CDK1 expression, extracts of
regenerating livers at 40 and 72 h post-PH were used. The
expression of mGSTA4 in controls versus treatments was
quantified by densitometry: *, p < 0.01; **,
p < 0.001. AU, arbitrary units.
|
|
Thus, we postulated that the cell cycle priming factors, TNF
and
IL-6, produced within 15 min post-PH, and survival/growth factor EGF,
which cooperates with TNF
and IL-6 to induce progression through the cell cycle and favor survival of hepatocytes (1), could be
involved in this induction. TNF
and IL-6 injections to normal mice
induced expression of mGSTA4 but not mGSTA1, used as control, compared
with mice injected with the vehicle only (Fig. 4C).
In normal livers at 6 and 24 h after EGF administration,
expression of mGSTA4 was significantly induced compared with the levels
of mGSTA4 in livers of mice injected with the vehicle and noninjected
animals (Fig. 4D). To determine whether EGF also induced proliferation of liver cells, expression of CDK1 protein, a cell cycle
marker of S, G2, and M phases (9, 10), was studied and
compared with its expression in regenerating livers at 40 and 72 h
post-PH. In livers of control and EGF-treated mice, CDK1 was not
detected, whereas its expression was strongly induced in regenerating
livers. These results indicated that TNF
, IL-6, and EGF up-regulated
mGSTA4 expression in normal liver.
TNF
, IL-6, and EGF Induce mGSTA4 Expression in
Primary Cultures of Mouse Hepatocytes--
Primary cultures of mouse
hepatocytes were used to confirm the up-regulation of mGSTA4 by TNF
,
IL-6, and EGF and analyze the level of regulation.
The addition of TNF
and IL-6 to the culture medium at 24 h led
to induction of the mGSTA4 protein, whereas the levels of mGSTA1 and
albumin, used as controls, were unaffected (Fig.
5A). Stimulation by EGF at 4 or 24 h after plating transiently induced mGSTA4 at 24 and 48 h, respectively, whereas the level of mGSTA1 was not increased after
EGF stimulation (Fig. 5B). To verify if stimulation by these
factors resulted in an increase in mGSTA4 mRNA levels, a Northern
blot analysis using mGSTA4 cDNA was performed on EGF-, TNF
-, and
IL-6-treated hepatocytes. Induction of mGSTA4 mRNAs by EGF, TNF
,
and IL-6 was confirmed (Fig. 5C).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 5.
Up-regulation of mGSTA4 expression by EGF,
IL-6, and TNF in primary cultures of mouse
hepatocytes. A, Western blot analysis of mGSTA4, A1,
and albumin expression in untreated hepatocytes (CONTROL)
or in hepatocytes exposed to IL-6 (20 ng/ml) or TNF (20 ng/ml). Cytokines were added 24 h after cell seeding, and
hepatocytes were harvested 6 h after treatments. B,
Western blot analysis of mGSTA4 and A1 expression in hepatocytes
treated (+) or not ( ) with EGF (50 ng/ml) and analyzed at the
indicated times after plating. Stimulation by EGF was performed at
either 4 or 24 h after plating. C, Northern blot
analysis of mGSTA4 in untreated hepatocytes or in those stimulated by
EGF, TNF , or IL-6. Treatments were performed for 6 h starting
24 h after plating. These data are representative of three
independent experiments. D, Hepatocytes were transfected
with plasmids carrying the 1.5-kb proximal promoter
(pGL3-GSTA4(-1571)) or deleted the promoter
(pGL3-GSTA4(1-165)) of the hGSTA4
upstream luciferase reporter gene. Cells were exposed to EGF for
24 h after a 4-h transfection and to TNF or IL-6 for 6 or
18 h, respectively, after transfection. At 48 h of
culture, cells were harvested and lysed for luciferase activity assays.
Values are means ± S.D. of three independent experiments.
Statistical significance was calculated between control and treated
cells transfected with the pGL3- GSTA4(1-1571) plasmid. **,
p < 0.01 with EGF and IL-6 treatments.
Inset, negative (pGL3 basic) and positive
(pGL3 prom) firefly luciferase controls.
|
|
To determine whether the induction of mGSTA4 by these soluble factors
occurred at the transcriptional level, transfection experiments were
performed using the human GSTA4 promoter, which we had previously
isolated and characterized (35). A significant increase in luciferase
activities was observed after stimulation with EGF and IL-6, but not
with TNF
, when cells were transfected with the pGL3-GSTA4-(1-1571)
plasmid carrying 1571 base pairs of the hGSTA4 promoter upstream of the
luciferase reporter gene (Fig. 5D), indicating that
induction of hGSTA4 by EGF and IL-6 was most likely due to a
transcriptional activation of the GSTA4 gene.
Proliferating and/or Survival Pathways Are Involved in the
Induction of mGSTA4 by EGF--
To confirm that proliferating and/or
survival pathways were involved in the induction of mGSTA4 expression
by EGF, we used inhibitors of different signaling pathways, namely Ly
294002, SB 203580, and U0126 which inhibit PI3K, p38 MAPK, and MEK,
respectively, and analyzed mGSTA4 expression by Western blot.
Treatments of EGF-stimulated hepatocytes by Ly 294002, SB 203580, and
U0126 led to a strong decrease in mGSTA4 protein expression, whereas
GSTA1 was not modified (Fig.
6A). Because interference between the PI3K and MEK/ERK pathways has been evidenced in many cell
types, the effects of these inhibitors on the phosphorylation of
AKT (P-AKT) and ERK1/2 (P-ERK), respective substrates of PI3K and MEK,
were investigated by Western blot (Fig. 6A). Ly 294002 was
found to strongly diminish P-AKT and P-ERK levels, whereas U0126 almost
completely abolished P-ERK and slightly decreased P-AKT. SB 203580 affected neither P-AKT nor P-ERK. In addition, these three molecules
strongly inhibited DNA replication in EGF-stimulated hepatocytes (Fig.
6B).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of mGSTA4 expression by inhibitors
of PI3K (Ly 294002), P-p38 MAPK (SB 203580), and MEK (U0126) in
EGF-stimulated hepatocytes. A, Western blot analysis of
mGSTA4, A1, P-AKT, P-ERK, and total ERK expression. Twenty-four hours
after plating, hepatocytes were treated with 15 µM PI3K
inhibitor Ly 294002, 12 µM p38 inhibitor SB 203580, or 50 µM MEK inhibitor U0126. One hour later, the cells were
stimulated with EGF and were harvested at 48 h of culture. P-ERK
membranes was reprobed with anti-total ERK. B,
[Methyl-3H]thymidine incorporation between 48 and 72 h of culture into DNA of unstimulated hepatocytes
(Control) or those stimulated by EGF for 72 h in the
presence or absence of Ly 294002, SB 203580, or U0126 inhibitor.
C, Hepatocytes transfected with the pGL3-GSTA4-(1-1571)
plasmid were treated or not with 50 ng/ml EGF in the absence
(Control) or presence of Ly 294002, SB 203580, or U0126 at
the concentrations indicated above. Luciferase activity was normalized
to that of the cotransfected plasmid expressing firefly luciferase.
Data are presented as the means ± S.D. of three experiments:
p < 0.001 and p < 0.01 between
controls and Ly 294002 or U0126 and SB 203580, respectively, in basal
condition without EGF; ***, p < 0.001 between control
versus Ly 294002 and U0126, **, p < 0.01 between control and SB 203580 in EGF-stimulated cells.
|
|
The ability of these inhibitors to down-regulate hGSTA4 transcriptional
activity by transient transfection of pGL3-GSTA4-(1-1571) plasmid was
investigated. Four hours after transfection, hepatocytes were treated
with SB 203580, Ly 294002, and U0126 in the absence or presence of EGF
for 24 h. As expected, luciferase activity was enhanced in the
presence of EGF. SB 203580 slightly decreased luciferase activities in
both nonstimulated and EGF-stimulated cells, whereas treatments by Ly
294002 and U0126 strongly down-regulated reporter gene activity in both
nonstimulated and EGF-stimulated cultures (Fig. 6C).
 |
DISCUSSION |
Liver regeneration following partial hepatectomy is associated
with an overproduction of ROS, which probably play a critical role in
the induction of hepatocyte proliferation (1). Several mechanisms of
defense are activated to neutralize this ROS excess (12, 13). Among the
protective defense systems in hepatocytes, GSTs, particularly GSTA4,
are recognized to play an important role in the elimination of
lipoperoxidation products in various physiopathological situations (39,
40).
Only a few studies have dealt with the regulation of GSTs during liver
cell growth without detailed kinetics of GST expression during the
first 3 days post-PH (28, 29). Our results have clearly demonstrated
for the first time that several GSTs belonging to distinct classes, in
particular mGSTA4, exhibit a biphasic pattern of induction concomitant
with the two critical steps of liver regeneration, i.e.
entry into the cell cycle (the so-called priming) and the commitment to
DNA synthesis, which are controlled by the pro-inflammatory
cytokines TNF
and IL-6 and by growth factors, respectively
(1).
Oxidative stress, demonstrated by H2O2
production in mitochondria (13) and increased levels of MDA and 4-HNE
products in cytoplasm detected in this study, is observed in early
G1 phase during liver regeneration. We postulated that this
increase in lipid peroxidation products was associated with an increase
in mitochondrial and/or cytosolic mGSTA4 content. Several recent studies have dealt with immunolocalization of GSTA4 in hepatocytes and
led to contradictory results. This enzyme has been reported to be
located in both mitochondria and cytosol (41), only in mitochondria
(42), or predominantly at or near the plasma membrane (43). Our
observations based on both immunofluorescence confocal microscopy and
subcellular fractionation support a distribution of mGSTA4 in both
mitochondria and cytosol and a preferential increase of mGSTA4 content
in the cytosol of regenerating hepatocytes. The mitochondrial and
cytosolic localization of mGSTA4 is compatible with the formation of
ROS in mitochondria and lipid peroxidation-derived aldehydes in
membranes that diffuse within the cell and attack targets far from the
site of their original production.
The induction of mGSTA4 during the first hour post-PH could result from
oxidative stress, because 4-HNE is known to be substrate and inducer of
this GST isoform (25, 38). However, our results show that, in both
normal and regenerating liver, NIL, a specific inhibitor of iNOS,
diminished the levels of 4-HNE and MDA, whereas mGSTA4 protein content
was unchanged or augmented in regenerating and normal liver,
respectively. These findings favor the conclusion that the expression
of mGSTA4 is not strictly correlated to the levels of lipid
peroxidation and more precisely to the contents of 4-HNE and/or MDA.
Nevertheless, it cannot be totally excluded that free radicals rather
than lipoperoxidation products may contribute to the up-regulation of
mGSTA4 during liver regeneration.
In the regenerating liver, induction through NF
B activation (17) of
cellular defenses involved in the neutralization of the excess of ROS
and lipid peroxidation products, such as the mitochondrial UCP-2
protein (13), iNOS (14), and the anti-apoptotic proteins
BclXL and Akt (44, 45), are dependent upon
stimulation by the pro-inflammatory cytokines TNF
and IL-6 and the
growth/survival factors transforming growth factor-
, hepatocyte
growth factor, and EGF. Here, we show that injection of TNF
, IL-6,
and EGF to normal mice resulted in an induction of mGSTA4, whereas
mGSTA1 remained unchanged. The biphasic induction of mGSTA4 during the first hours after PH could result from the overproduction of the pro-inflammatory cytokines TNF
and IL-6 involved in the cell cycle
priming and activation of survival pathways by growth factors such as
EGF. This hypothesis is strongly reinforced by our in vitro
data, demonstrating that mGSTA4 expression was also increased after
stimulation by TNF
, IL-6, and EGF. The second peak of induction of
mGSTA4, occurring between 24 and 48 h post-PH, could be due to the
increase in growth factors in plasma that promotes the G1/S
transition (11). However, our data indicated that mGSTA4 induction by
EGF is not necessarily correlated to progression in late G1
or S phases. Indeed, in vivo injection of EGF induced mGSTA4, whereas hepatocytes did not proliferate, as previously reported
(1) and confirmed in this study by the absence of CDK1 expression, a
cell cycle marker of S, G2, and M phases (9).
Previous studies have demonstrated modulation of GST expression by
cytokines and growth factors in the liver. An increase in hGSTA1 and A2
by IL-4 in cultured human hepatocytes (46) and a marked decrease in
rGSTA2 and M1 mRNA levels by IL-1
in rat hepatocytes (47) have
been evidenced. Moreover, rGSTP1 expression is strongly induced by EGF
in cultured rat hepatocytes (48). However, this is the first time, to
our knowledge, that induction of several GSTs has been evidenced during
liver regeneration and that a correlation has been established between
this induction and the soluble factors essential for hepatocyte
survival and proliferation.
Our results also suggest that IL-6 and EGF positively regulate hGSTA4
expression at the transcriptional level, whereas TNF
could act
rather at a post-transcriptional level as previously shown for IL-1
on rGSTA2 and M1 regulation (47) in rat hepatocytes. Another hypothesis
can be proposed to explain why TNF
did not induce luciferase
activity after transfection with the 1.5-kb hGSTA4 sequence promoter.
Indeed, in a previous study, we found several putative binding sites
for AP1, Sp1, and STAT as well as NF
B within the 1.5-kb sequence
upstream of the transcription start site of the hGSTA4 gene
(35). More recently, we localized several other putative binding sites
for transcriptional factors, including NF
B, AP1, and CREB (cAMP
response element-binding protein), within the 0.5 kb upstream of the
promoter region used for our transfection assays (data not shown).
Therefore, we cannot rule out that TNF
could activate hGSTA4
transcription via the putative NF
B binding site located upstream of
the 1.5-kb promoter sequence.
The p42/44 ERK1/2 (11), p38 MAPK (49), and PI3K (44) signaling pathways
activated during liver regeneration are essential for both the
proliferation and survival of hepatocytes during the hepatic
regenerative process. Recently, several reports have indicated that
MAPK pathways are involved in the regulation of GST enzymes. Indeed,
Kang et al. (50) have demonstrated that the activation of
p38 MAPK and PI3K during oxidative stress leads to the induction of
rGSTA2. In addition, Yin et al. (51) have demonstrated that
GSTPi has protective effects against
H2O2-mediated cell death via activation of p38
MAPK, ERK, and NF
B and repression of the c-jun N-terminal
kinase signaling pathways. Here, we have shown that the use of the
specific inhibitors Ly 294002, U0126, and SB 203580 of the protein
kinases PI3K, MEK, and p38 MAPK, respectively, prevented the induction
of mGSTA4 expression and the transcriptional activation of the hGSTA4
promoter-luciferase construct by EGF.
Altogether, these data demonstrate the induction of several GST
isoforms, including mGSTA1, A4, Mu, and Pi, during liver regeneration. They also strongly suggest that the pro-inflammatory cytokines TNF
and IL-6 and the growth/survival factor EGF, which control hepatocyte
survival and proliferation during liver regeneration, might be involved
in the up-regulation of mGSTA4 via PI3K and/or MAPK pathways. Thus,
mGSTA4 could be a target gene induced by survival factors
and could contribute to cellular defenses against oxidative stress in hepatocyte.
 |
FOOTNOTES |
*
This work was supported by the "Institut National de la
Santé et de la Recherche Médicale" and the "Association
pour la Recherche contre le Cancer" (Grant 5333).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: INSERM U456,
Faculté de Pharmacie, 2 Ave. du Pr. Léon Bernard, 35043 Rennes Cedex, France. Tel.: 33-2-23-23-47-91; Fax: 33-2-23-23-47-94; E-mail: Andre.guillouzo@rennes.inserm.fr.
Published, JBC Papers in Press, March 7, 2002, DOI 10.1074/jbc.M112351200
 |
ABBREVIATIONS |
The abbreviations used are:
TNF
, tumor
necrosis factor
;
NIL, L-N6-1-iminoethyl-lysine
dihydrochloride;
IL-6, interleukin 6;
NF
B, nuclear factor for the
chain of B cells;
STAT, signal transducer and activator of
transcription;
AP1, activating protein-1;
bp, base pairs;
EGF, epidermal growth factor;
CDK1, cyclin-dependent kinase 1;
MAPK, mitogen-activated protein kinase;
ERK, extracellular
signal-regulated protein;
MEK, MAPK/ERK kinase;
PI3K, phosphoinositide
3-kinase;
ROS, reactive oxygen species;
iNOS, inducible nitric-oxide
synthase;
GST, glutathione S-transferase;
4-HNE, 4-hydroxynonenal;
MDA, malondialdehyde;
CDNB, 1-chloro-2,4-dinitrobenzene;
EA, ethacrynic acid;
PH, partial
hepatectomy;
PBS, phosphate-buffered saline;
h, human;
m, murine;
P-, phosphorylated.
 |
REFERENCES |
| 1.
|
Fausto, N.
(2000)
J. Hepatol.
32,
19-31[Medline]
[Order article via Infotrieve]
|
| 2.
|
Yamada, Y.,
Kirillova, I.,
Peschon, J. J.,
and Fausto, N.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
1441-1446[Abstract/Free Full Text]
|
| 3.
|
Webber, E. M.,
Bruix, J.,
Pierce, R. H.,
and Fausto, N.
(1998)
Hepatology
28,
1226-1234[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Cressman, D. E.,
Greenbaum, L. E.,
DeAngelis, R. A.,
Ciliberto, G.,
Furth, E. E.,
Poli, V.,
and Taub, R.
(1996)
Science
274,
1379-1383[Abstract/Free Full Text]
|
| 5.
|
FitzGerald, M. J.,
Webber, E. M.,
Donovan, J. R.,
and Fausto, N.
(1995)
Cell Growth & Differ.
6,
417-427[Abstract]
|
| 6.
|
Cressman, D. E.,
Diamond, R. H.,
and Taub, R.
(1995)
Hepatology
21,
1443-1449[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Heinrich, P. C.,
Behrmann, I.,
Muller-Newen, G.,
Schaper, F.,
and Graeve, L.
(1998)
Biochem. J.
334,
297-314[Medline]
[Order article via Infotrieve]
|
| 8.
|
Yamada, Y.,
Webber, E. M.,
Kirillova, I.,
Peschon, J. J.,
and Fausto, N.
(1998)
Hepatology
28,
959-970[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Loyer, P.,
Cariou, S.,
Glaise, D.,
Bilodeau, M.,
Baffet, G.,
and Guguen-Guillouzo, C.
(1996)
J. Biol. Chem.
271,
11484-11492[Abstract/Free Full Text]
|
| 10.
|
Albrecht, J. H.,
and Hansen, L. K.
(1999)
Cell Growth & Differ.
10,
397-404[Abstract/Free Full Text]
|
| 11.
|
Talarmin, H.,
Rescan, C.,
Cariou, S.,
Glaise, D.,
Zanninelli, G.,
Bilodeau, M.,
Loyer, P.,
Guguen-Guillouzo, C.,
and Baffet, G.
(1999)
Mol. Cell. Biol.
19,
6003-6011[Abstract/Free Full Text]
|
| 12.
|
Rai, R. M.,
Lee, F. Y.,
Rosen, A.,
Yang, S. Q.,
Lin, H. Z.,
Koteish, A.,
Liew, F. Y.,
Zaragoza, C.,
Lowenstein, C.,
and Diehl, A. M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13829-13834[Abstract/Free Full Text]
|
| 13.
|
Lee, F. Y., Li, Y.,
Zhu, H.,
Yang, S.,
Lin, H. Z.,
Trush, M.,
and Diehl, A. M.
(1999)
Hepatology
29,
677-687[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Carnovale, C. E.,
Scapini, C.,
Alvarez, M. L.,
Favre, C.,
Monti, J.,
and Carrillo, M. C.
(2000)
J. Hepatol.
32,
798-804[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Chandel, N. S.,
Schumacker, P. T.,
and Arch, R. H.
(2001)
J. Biol. Chem.
276,
42728-42736[Abstract/Free Full Text]
|
| 16.
|
Schulze-Osthoff, K.,
Bakker, A. C.,
Vanhaesebroeck, B.,
Beyaert, R.,
Jacob, W. A.,
and Fiers, W.
(1992)
J. Biol. Chem.
267,
5317-5323[Abstract/Free Full Text]
|
| 17.
|
Plumpe, J.,
Malek, N. P.,
Bock, C. T.,
Rakemann, T.,
Manns, M. P.,
and Trautwein, C.
(2000)
Am. J. Physiol.
278,
G173-G183
|
| 18.
|
Chao, D. T.,
and Korsmeyer, S. J.
(1998)
Annu. Rev. Immunol.
16,
395-419[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Diaz-Guerra, M. J.,
Velasco, M.,
Martin-Sanz, P.,
and Bosca, L.
(1997)
Biochem. J.
326,
791-797[Medline]
[Order article via Infotrieve]
|
| 20.
|
Li, J.,
Bombeck, C. A.,
Yang, S.,
Kim, Y. M.,
and Billiar, T. R.
(1999)
J. Biol. Chem.
274,
17325-17333[Abstract/Free Full Text]
|
| 21.
|
Teshigawara, M.,
Matsumoto, S.,
Tsuboi, S.,
and Ohmori, S.
(1995)
Res. Exp. Med.
195,
55-60[Medline]
[Order article via Infotrieve]
|
| 22.
|
Hayes, J. D.,
and Strange, R. C.
(1995)
Free Radic. Res.
22,
193-207[Medline]
[Order article via Infotrieve]
|
| 23.
|
Yang, Y.,
Cheng, J. Z.,
Singhal, S. S.,
Saini, M.,
Pandya, U.,
Awasthi, S.,
and Awasthi, Y. C.
(2001)
J. Biol. Chem.
276,
19220-19230[Abstract/Free Full Text]
|
| 24.
|
Jensson, H.,
Guthenberg, C.,
Alin, P.,
and Mannervik, B.
(1986)
FEBS Lett.
203,
207-209[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Goon, D.,
Saxena, M.,
Awasthi, Y. C.,
and Ross, D.
(1993)
Toxicol. Appl. Pharmacol.
119,
175-180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Cheng, J. Z.,
Singhal, S. S.,
Saini, M.,
Singhal, J.,
Piper, J. T.,
Van Kuijk, F. J.,
Zimniak, P.,
Awasthi, Y. C.,
and Awasthi, S.
(1999)
Arch. Biochem. Biophys.
372,
29-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Desmots, F.,
Rissel, M.,
Pigeon, C.,
Loyer, P.,
Loréal, O.,
and Guillouzo, A.
(2002)
Free Radic. Biol. Med.
32,
93-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Lee, S. J.,
and Boyer, T. D.
(1993)
Biochem. J.
293,
137-142[Medline]
[Order article via Infotrieve]
|
| 29.
|
Mori, M.,
Ishizaki, M.,
and Onda, M.
(1995)
Nippon Ika Daigaku Zasshi
62,
447-455[Medline]
[Order article via Infotrieve]
|
| 30.
|
Desmots, F.,
Rissel, M.,
Loyer, P.,
Turlin, B.,
and Guillouzo, A.
(2001)
J. Histochem. Cytochem.
49,
1573-1580[Abstract/Free Full Text]
|
| 31.
|
Guguen, C.,
Guillouzo, A.,
Boisnard, M., Le,
Cam, A.,
and Bourel, M.
(1975)
Biol. Gastroenterol. (Paris)
8,
223-231[Medline]
[Order article via Infotrieve]
|
| 32.
|
Boitier, E.,
Merad-Boudia, M.,
Guguen-Guillouzo, C.,
Defer, N.,
Ceballos-Picot, I.,
Leroux, J. P.,
and Marsac, C.
(1995)
Cancer Res.
55,
3028-3035[Abstract/Free Full Text]
|
| 33.
|
Habig, W. H.,
and Jakoby, W. B.
(1981)
Methods Enzymol.
77,
398-405[Medline]
[Order article via Infotrieve]
|
| 34.
|
Satoh, K.
(1995)
Carcinogenesis
16,
869-874[Abstract/Free Full Text]
|
| 35.
|
Desmots, F.,
Rauch, C.,
Henry, C.,
Guillouzo, A.,
and Morel, F.
(1998)
Biochem. J.
336,
437-442[Medline]
[Order article via Infotrieve]
|
| 36.
| Gilot, D., Miramon, M. L., Benvegnu, T., Ferrieres, V., Loreal,
O., Guguen-Guillouzo, C., Plusquellec, D., and Loyer, P. (2002)
J. Gene Med., in press
|
| 37.
|
Albrecht, J. H.,
Hoffman, J. S.,
Kren, B. T.,
and Steer, C. J.
(1993)
Am. J. Physiol.
265,
G857-G864[Medline]
[Order article via Infotrieve]
|
| 38.
|
Tjalkens, R. B.,
Luckey, S. W.,
Kroll, D. J.,
and Petersen, D. R.
(1998)
Arch. Biochem. Biophys.
359,
42-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Hayes, J. D.,
and Pulford, D. J.
(1995)
Crit. Rev. Biochem. Mol. Biol.
30,
445-600[Medline]
[Order article via Infotrieve]
|
| 40.
|
Awasthi, Y. C.,
Sharma, R.,
and Singhal, S. S.
(1994)
Int. J. Biochem.
26,
295-308[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Bhagwat, S. V.,
Vijayasarathy, C.,
Raza, H.,
Mullick, J.,
and Avadhani, N. G.
(1998)
Biochem. Pharmacol.
56,
831-839[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Gardner, J. L.,
and Gallagher, E. P.
(2001)
Arch. Biochem. Biophys.
390,
19-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Singh, S. P.,
Janecki, A. J.,
Srivastava, S. K.,
Awasthi, S.,
Awasthi, Y. C.,
Xia, S. J.,
and Zimniak, P.
(2002)
J. Biol. Chem.
277,
4232-4239[Abstract/Free Full Text]
|
| 44.
|
Hong, F.,
Nguyen, V. A.,
Shen, X.,
Kunos, G.,
and Gao, B.
(2000)
Biochem. Biophys. Res. Commun.
279,
974-979[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Tzung, S. P.,
Fausto, N.,
and Hockenbery, D. M.
(1997)
Am. J. Pathol.
150,
1985-1995[Abstract]
|
| 46.
|
Langouet, S.,
Corcos, L.,
Abdel-Razzak, Z.,
Loyer, P.,
Ketterer, B.,
and Guillouzo, A.
(1995)
Biochem. Biophys. Res. Commun.
216,
793-800[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Maheo, K.,
Antras-Ferry, J.,
Morel, F.,
Langouet, S.,
and Guillouzo, A.
(1997)
J. Biol. Chem.
272,
16125-16132[Abstract/Free Full Text]
|
| 48.
|
Fardel, O.,
Loyer, P.,
Morel, F.,
Ratanasavanh, D.,
and Guillouzo, A.
(1992)
Biochem. Pharmacol.
44,
2259-2262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Spector, M. S.,
Auer, K. L.,
Jarvis, W. D.,
Ishac, E. J.,
Gao, B.,
Kunos, G.,
and Dent, P.
(1997)
Mol. Cell. Biol.
17,
3556-3565[Abstract]
|
| 50.
|
Kang, K. W.,
Ryu, J. H.,
and Kim, S. G.
(2000)
Mol. Pharmacol.
58,
1017-1025[Abstract/Free Full Text]
|
| 51.
|
Yin, Z.,
Ivanov, V. N.,
Habelhah, H.,
Tew, K.,
and Ronai, Z.
(2000)
Cancer Res.
60,
4053-4057[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. N. Jackson, S. D. Larson, S. R. Silva, P. G. Rychahou, L. A. Chen, S. Qiu, S. Rajaraman, and B. M. Evers
PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy
Am J Physiol Gastrointest Liver Physiol,
June 1, 2008;
294(6):
G1401 - G1410.
[Abstract]
[Full Text]
[PDF]
|
 |
|